Literature DB >> 27101529

Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.

Salomon Manier1, Yawara Kawano, Giada Bianchi, Aldo M Roccaro, Irene M Ghobrial.   

Abstract

PURPOSE OF REVIEW: Multiple myeloma is a plasma cell malignancy evolving in the bone marrow and leading to end organ damage such as bone lesions, cytopenias, and kidney failure. This review delineates recent advances in the molecular mechanisms leading to tumor progression in multiple myeloma. Two different aspects enable tumor expansion: cell autonomous through genomic alterations in the tumor clone and noncell autonomous deregulations in the bone marrow tumor microenvironment. These alterations provide the framework for the continuous progression of multiple myeloma from early precursor conditions such as monoclonal gammopathy of undetermined significance and smoldering multiple myeloma to overt multiple myeloma. RECENT
FINDINGS: In this review, we discuss recent findings in the genomic alterations that occur in the tumor clone such as somatic genomic mutations, copy number variation and chromosomal translocation, and delineate noncell autonomous deregulations in which tumor cells take advantage of a permissive microenvironment to further proliferate. The latter compartment includes interaction with bone marrow stromal cells, osteoblasts, osteoclasts, and immune escape.
SUMMARY: Understanding the mechanisms that lead tumor progression from early stages to overt multiple myeloma could guide to more effective therapies and therefore prevent disease progression.

Entities:  

Mesh:

Year:  2016        PMID: 27101529     DOI: 10.1097/MOH.0000000000000259

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  9 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

2.  DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.

Authors:  Duncan R Hewett; Kate Vandyke; David M Lawrence; Natasha Friend; Jacqueline E Noll; Joel M Geoghegan; Peter I Croucher; Andrew C W Zannettino
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

3.  Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.

Authors:  Christine Lam; Ian D Ferguson; Margarette C Mariano; Yu-Hsiu T Lin; Megan Murnane; Hui Liu; Geoffrey A Smith; Sandy W Wong; Jack Taunton; Jun O Liu; Constantine S Mitsiades; Byron C Hann; Blake T Aftab; Arun P Wiita
Journal:  Haematologica       Date:  2018-04-05       Impact factor: 9.941

4.  Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Authors:  Ajai Chari; Robert F Cornell; Cristina Gasparetto; Chatchada Karanes; Jeffrey V Matous; Ruben Niesvizky; Matthew Lunning; Saad Z Usmani; Larry D Anderson; Saurabh Chhabra; Saulius Girnius; Chaim Shustik; Robert Stuart; Yihua Lee; Zeena Salman; Emily Liu; Jason Valent
Journal:  Hematol Oncol       Date:  2020-03-11       Impact factor: 5.271

Review 5.  CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.

Authors:  Alberto L Horenstein; Cristiano Bracci; Fabio Morandi; Fabio Malavasi
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

6.  International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).

Authors:  María-Victoria Mateos; Shaji Kumar; Meletios A Dimopoulos; Verónica González-Calle; Efstathios Kastritis; Roman Hajek; Carlos Fernández De Larrea; Gareth J Morgan; Giampaolo Merlini; Hartmut Goldschmidt; Catarina Geraldes; Alessandro Gozzetti; Charalampia Kyriakou; Laurent Garderet; Markus Hansson; Elena Zamagni; Dorotea Fantl; Xavier Leleu; Byung-Su Kim; Graça Esteves; Heinz Ludwig; Saad Usmani; Chang-Ki Min; Ming Qi; Jon Ukropec; Brendan M Weiss; S Vincent Rajkumar; Brian G M Durie; Jesús San-Miguel
Journal:  Blood Cancer J       Date:  2020-10-16       Impact factor: 11.037

7.  Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.

Authors:  Marc S Raab; Karsten Rippe; Stephan M Tirier; Jan-Philipp Mallm; Simon Steiger; Alexandra M Poos; Mohamed H S Awwad; Nicola Giesen; Nicola Casiraghi; Hana Susak; Katharina Bauer; Anja Baumann; Lukas John; Anja Seckinger; Dirk Hose; Carsten Müller-Tidow; Hartmut Goldschmidt; Oliver Stegle; Michael Hundemer; Niels Weinhold
Journal:  Nat Commun       Date:  2021-11-29       Impact factor: 14.919

Review 8.  Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.

Authors:  Barbara Castella; Myriam Foglietta; Chiara Riganti; Massimo Massaia
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

9.  MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients.

Authors:  Ying Bao; Mingqin Wei; Xiaohong Ji
Journal:  J Clin Lab Anal       Date:  2020-01-06       Impact factor: 2.352

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.